Artia is Launching 50% of the Top 10 Most Anticipated Drug Launches of 2023
Each year, Evaluate Vantage projects significant events in the biopharmaceuticals market. Among these projections are sales forecasts for products five years after their launches. FiercePharma turns these projections into a top ten list of the most anticipated drug launches, with the 2023 version posted earlier this month.
Upon our review at Artia, we could not help but notice that despite being only two months into 2023, we are already in the process of launching half of FiercePharma’s list in Medicaid!
Artia has been a fixture in Medicaid market access for 18 years. One of our most popular business lines is guiding drug launches in Medicaid, as evidenced by our 50% coverage of FiercePharma’s list. This continues the recognition of Artia as the Medicaid market access leader. In both 2021 and 2022, we orchestrated the Medicaid launch of one-third of the products approved by the FDA – a figure we have already surpassed in 2023!
The staff of Artia Solutions possesses an unrivaled level of experience and expertise in Medicaid pharmacy practice. Our team consists of former state Medicaid pharmacy directors and administrators, Medicaid PBM executives, pharmaceutical manufacturer Medicaid market access directors, and many more who have spent years at Artia.
We are ready to provide you with the plan for optimal Medicaid market access for your products whether they are a glimmer in your eye or an established market presence. Contact us.
About the Author
Changes to New York’s Rebate Programs
Manufacturers are often intimidated when directed by New York to participate in Medicaid, due to the uniqueness of their programs. We aim to eliminate confusion in navigating these processes to resolution. In this blog post, we’ll walk you through a summary of the most recent changes to the New York Medicaid programs.
State Medicaid Programs Retake Pharmacy Controls
State Medicaid programs’ relationships with managed care organizations that serve Medicaid recipients continue to evolve. Just when it appears that trends are slowing or stabilizing, a new method is introduced. The latest development could overlap existing state controls to bring even more pharmacy control back to state management.
Reimbursement Challenges with High-Cost Inpatient Drugs
The management and reimbursement of inpatient drug costs in Medicaid programs are pivotal topics, especially with the proliferation of high-cost therapies. The emergence of expensive inpatient drugs, such as cell and gene therapies, have challenged Diagnosis Related Groups (DRGs), the traditional bundled payment system used by hospitals.